-
Statin use among cancer patients with diverse malignancies is associated with reduced cancer-related mortality. The mechanism is plausible since statins inhibit cholesterol synthesis, which reduces the pool of compounds necessary in cellular proliferation and maintenance of critical cellular functions, such as membrane integrity, signaling, protein synthesis, and cell cycle progression. Prospective clinical trials are warranted.
-
Omalizumab for Asthma in Real Life; Tenofovir: New Hope for Hepatitis B Patients; H. pylori: Frequency of Recurrence After Successful Eradication
-
The first in a new class of drugs has been approved by the FDA for the treatment of diabetes mellitus. This new class of drugs decreases the renal threshold for glucose excretion by inhibiting the sodium-glucose co-transporter 2 (SGLT2), thus increasing renal clearance of glucose. Canagliflozin is licensed from Mitsubishi Tanabe Pharma Corporation and marketed by Janssen Pharmaceuticals as Invokana.
-
The Biventricular vs Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block (BLOCK HF) trial tested the hypothesis that biventricular pacing (cardiac resynchronization therapy [CRT]) would be superior to right ventricular pacing in patients with mild-to-moderate heart failure, left ventricular systolic dysfunction, and an indication for full-time ventricular pacing.
-
The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial was completed more than 10 years ago.
-
Patients seen in emergency departments (ED) for acute chest pain who are deemed low risk for acute coronary syndrome (ACS) and relatively safe for discharge are often referred to their primary care physician (PCP) for follow-up.
-
-
Beta-blockers and noncardiac surgery; prenatal medication exposure and risk of autism; reasons for statin discontinuations; and FDA actions.
-
-
Guideline-driven earlier mitral valve repair for patients with mitral regurgitation (MR) due to degenerative disease has increased in the last 25 years.
